182 related articles for article (PubMed ID: 12368679)
1. Regulation of herpes simplex virus 1 replication using tumor-associated promoters.
Mullen JT; Kasuya H; Yoon SS; Carroll NM; Pawlik TM; Chandrasekhar S; Nakamura H; Donahue JM; Tanabe KK
Ann Surg; 2002 Oct; 236(4):502-12; discussion 512-3. PubMed ID: 12368679
[TBL] [Abstract][Full Text] [Related]
2. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen.
Kasuya H; Pawlik TM; Mullen JT; Donahue JM; Nakamura H; Chandrasekhar S; Kawasaki H; Choi E; Tanabe KK
Cancer Res; 2004 Apr; 64(7):2561-7. PubMed ID: 15059912
[TBL] [Abstract][Full Text] [Related]
3. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
4. Herpes simplex virus type 1 origins of DNA replication play no role in the regulation of flanking promoters.
Summers BC; Leib DA
J Virol; 2002 Jul; 76(14):7020-9. PubMed ID: 12072502
[TBL] [Abstract][Full Text] [Related]
5. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
Griffith C; Noonan S; Lou E; Shillitoe EJ
Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.
Kurihara T; Brough DE; Kovesdi I; Kufe DW
J Clin Invest; 2000 Sep; 106(6):763-71. PubMed ID: 10995787
[TBL] [Abstract][Full Text] [Related]
7. The role of ICP4 repressor activity in temporal expression of the IE-3 and latency-associated transcript promoters during HSV-1 infection.
Rivera-Gonzalez R; Imbalzano AN; Gu B; Deluca NA
Virology; 1994 Aug; 202(2):550-64. PubMed ID: 8030221
[TBL] [Abstract][Full Text] [Related]
8. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
[TBL] [Abstract][Full Text] [Related]
9. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.
Nakamura H; Kasuya H; Mullen JT; Yoon SS; Pawlik TM; Chandrasekhar S; Donahue JM; Chiocca EA; Chung RY; Tanabe KK
J Clin Invest; 2002 Apr; 109(7):871-82. PubMed ID: 11927614
[TBL] [Abstract][Full Text] [Related]
10. Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression.
Preston CM; Mabbs R; Nicholl MJ
Virology; 1997 Mar; 229(1):228-39. PubMed ID: 9123865
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HSV-1 replication and reactivation by the mutation-insensitive transcription inhibitor tetra-O-glycyl-nordihydroguaiaretic acid.
Park R; Giza PE; Mold DE; Huang RC
Antiviral Res; 2003 Mar; 58(1):35-45. PubMed ID: 12719005
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Properties of the LSD1 Inhibitor SP-2509.
Harancher MR; Packard JE; Cowan SP; DeLuca NA; Dembowski JA
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699090
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.
Deharvengt S; Wack S; Aprahamian M; Hajri A
J Gene Med; 2005 May; 7(5):672-80. PubMed ID: 15580629
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex type1:lacZ recombinant viruses. II. Microtiter plate-based colorimetric assays for the discovery of new antiherpes agents and the points at which such agents disrupt the viral replication cycle.
Dicker IB; Blasecki JW; Seetharam S
Antiviral Res; 1995 Nov; 28(3):213-24. PubMed ID: 8629814
[TBL] [Abstract][Full Text] [Related]
15. Role of the DR2 repeat array in the regulation of the ICP34.5 gene promoter of herpes simplex virus type 1 during productive infection.
Martin DW; Weber PC
J Gen Virol; 1998 Mar; 79 ( Pt 3)():517-23. PubMed ID: 9519830
[TBL] [Abstract][Full Text] [Related]
16. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
Grant KG; Krisky DM; Ataai MM; Glorioso JC
Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
[TBL] [Abstract][Full Text] [Related]
17. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
18. Two leaky-late HSV-1 promoters differ significantly in structural architecture.
Lieu PT; Wagner EK
Virology; 2000 Jun; 272(1):191-203. PubMed ID: 10873762
[TBL] [Abstract][Full Text] [Related]
19. The Telomerase Inhibitor MST-312 Interferes with Multiple Steps in the Herpes Simplex Virus Life Cycle.
Haberichter J; Roberts S; Abbasi I; Dedthanou P; Pradhan P; Nguyen ML
J Virol; 2015 Oct; 89(19):9804-16. PubMed ID: 26178994
[TBL] [Abstract][Full Text] [Related]
20. Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector.
Yao F; Theopold C; Hoeller D; Bleiziffer O; Lu Z
Mol Ther; 2006 Jun; 13(6):1133-41. PubMed ID: 16574491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
